HUE046873T2 - Peptidek és peptidomimetikumok rákos páciens alpopulációk kombinációs alkalmazásában és kezelésében - Google Patents

Peptidek és peptidomimetikumok rákos páciens alpopulációk kombinációs alkalmazásában és kezelésében

Info

Publication number
HUE046873T2
HUE046873T2 HUE14818523A HUE14818523A HUE046873T2 HU E046873 T2 HUE046873 T2 HU E046873T2 HU E14818523 A HUE14818523 A HU E14818523A HU E14818523 A HUE14818523 A HU E14818523A HU E046873 T2 HUE046873 T2 HU E046873T2
Authority
HU
Hungary
Prior art keywords
peptidomimetics
peptides
treatments
cancer patient
combination uses
Prior art date
Application number
HUE14818523A
Other languages
English (en)
Inventor
Takumi Kawabe
Naoki Mine
Naoya Saito
Keiichi Sakakibara
Takuji Sato
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52141164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE046873(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Publication of HUE046873T2 publication Critical patent/HUE046873T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14818523A 2013-06-24 2014-06-24 Peptidek és peptidomimetikumok rákos páciens alpopulációk kombinációs alkalmazásában és kezelésében HUE046873T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361838777P 2013-06-24 2013-06-24

Publications (1)

Publication Number Publication Date
HUE046873T2 true HUE046873T2 (hu) 2020-03-30

Family

ID=52141164

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14818523A HUE046873T2 (hu) 2013-06-24 2014-06-24 Peptidek és peptidomimetikumok rákos páciens alpopulációk kombinációs alkalmazásában és kezelésében

Country Status (28)

Country Link
US (1) US9221872B2 (hu)
EP (1) EP3013351B1 (hu)
JP (1) JP6401255B2 (hu)
KR (1) KR102247493B1 (hu)
CN (1) CN105324121A (hu)
AU (1) AU2014300713B2 (hu)
BR (1) BR112015032542A2 (hu)
CA (1) CA2916136C (hu)
CL (1) CL2015003704A1 (hu)
CY (1) CY1122523T1 (hu)
DK (1) DK3013351T3 (hu)
ES (1) ES2765300T3 (hu)
HK (1) HK1219905A1 (hu)
HR (1) HRP20192264T1 (hu)
HU (1) HUE046873T2 (hu)
IL (1) IL243266B (hu)
LT (1) LT3013351T (hu)
MX (1) MX366341B (hu)
MY (1) MY182232A (hu)
PH (1) PH12015502855A1 (hu)
PL (1) PL3013351T3 (hu)
PT (1) PT3013351T (hu)
RS (1) RS60180B1 (hu)
RU (1) RU2732440C2 (hu)
SG (1) SG11201510490VA (hu)
SI (1) SI3013351T1 (hu)
WO (1) WO2014207556A1 (hu)
ZA (1) ZA201600089B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
EP2968443B1 (en) 2013-03-15 2021-09-29 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
LT3143037T (lt) 2014-05-16 2021-10-11 Protagonist Therapeutics, Inc. Alfa4beta7 integrino tioeterio peptidų antagonistaii
CN113563423A (zh) 2014-07-17 2021-10-29 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US9809623B2 (en) 2014-10-01 2017-11-07 Protagonist Therapeutics, Inc. α4β7 peptide monomer and dimer antagonists
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
TWI805542B (zh) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 用於癌症治療之肽及擬肽與t細胞活化劑及/或查核點抑制劑之組合
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN109195618A (zh) 2016-03-23 2019-01-11 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2022000397A (es) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CR20220332A (es) 2020-01-15 2022-11-28 Janssen Biotech Inc Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
PE20240631A1 (es) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1483290T3 (da) * 2002-01-17 2008-11-03 Takeda Pharmaceutical Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger
US7148349B2 (en) * 2002-10-31 2006-12-12 Metabasis Therapeutics, Inc. Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
JP4705567B2 (ja) * 2003-06-25 2011-06-22 株式会社 キャンバス 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物
US20100112089A1 (en) 2008-05-14 2010-05-06 Takeda Pharmaceutical Company Limited Peptide compound and use thereof

Also Published As

Publication number Publication date
JP2016522245A (ja) 2016-07-28
US20150056301A1 (en) 2015-02-26
CL2015003704A1 (es) 2016-07-29
MX366341B (es) 2019-07-05
HK1219905A1 (zh) 2017-04-21
WO2014207556A1 (en) 2014-12-31
CY1122523T1 (el) 2021-01-27
AU2014300713B2 (en) 2019-02-14
DK3013351T3 (da) 2020-01-27
RU2732440C2 (ru) 2020-09-16
HRP20192264T1 (hr) 2020-03-06
LT3013351T (lt) 2020-01-10
PH12015502855B1 (en) 2016-04-04
RU2016101718A3 (hu) 2018-03-01
EP3013351A1 (en) 2016-05-04
KR20160021792A (ko) 2016-02-26
CN105324121A (zh) 2016-02-10
EP3013351B1 (en) 2019-10-30
MX2015017609A (es) 2016-04-15
NZ715285A (en) 2021-09-24
JP6401255B2 (ja) 2018-10-10
KR102247493B1 (ko) 2021-04-30
ZA201600089B (en) 2020-02-26
RS60180B1 (sr) 2020-06-30
US9221872B2 (en) 2015-12-29
CA2916136C (en) 2022-10-18
PT3013351T (pt) 2020-01-17
EP3013351A4 (en) 2017-03-01
CA2916136A1 (en) 2014-12-31
MY182232A (en) 2021-01-18
AU2014300713A1 (en) 2016-01-21
SG11201510490VA (en) 2016-01-28
BR112015032542A2 (pt) 2017-07-25
ES2765300T3 (es) 2020-06-08
SI3013351T1 (sl) 2020-03-31
IL243266B (en) 2019-11-28
RU2016101718A (ru) 2017-07-28
IL243266A0 (en) 2016-03-31
PL3013351T3 (pl) 2020-05-18
PH12015502855A1 (en) 2016-04-04

Similar Documents

Publication Publication Date Title
HK1219905A1 (zh) 組合使用並治療癌症患者亞群的肽和肽模擬物
IL276106A (en) Garp-binding proteins and their uses
ZA201505735B (en) Cancer drug and uses
IL242881B (en) A toxic substance for use in combination with radiation in cancer treatment
HK1222399A1 (zh) 具有抗衰老功效的肽及其用途
PT3058936T (pt) Composição peptídica e respetivos usos
GB201318170D0 (en) Proteins with Diagnostic and Therapeutic Uses
HK1222561A1 (zh) 用於腫瘤學的組合物和方法
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
HK1217022A1 (zh) 肽-樹脂結合物及其用途
PL3071192T3 (pl) Związek kurkufenol do zastosowania w leczeniu nowotworu
SG11201502584XA (en) Peptides and methods for treating cancer
HK1220693A1 (zh) 碳水化合物改性的糖蛋白及其用途
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
HK1223631A1 (zh) 預防和治療炎症的小分子多肽及其應用
GB201308753D0 (en) Compounds and their use in therapy
IL243091B (en) Compositions and methods for use in oncology
EP2968398B8 (en) Modified hyaluronan and uses thereof in cancer treatment
GB2519829B (en) Methods for monitoring treatment response and relapse in breast cancer
GB201322958D0 (en) Uses of oligouronates in cancer treatment
AU2013901916A0 (en) An Agent and Use Thereof in Therapy
GB201308217D0 (en) Compounds and their use in therapy
GB201301640D0 (en) Methods and peptides